Literature DB >> 32767049

Radiomics derived from dynamic contrast-enhanced MRI pharmacokinetic protocol features: the value of precision diagnosis ovarian neoplasms.

Xiao-Li Song1, Jia-Liang Ren2, Dan Zhao1, Lifang Wang3, Honghong Ren1, Jinliang Niu4.   

Abstract

OBJECTIVES: To evaluate the efficiency of 2- and 3-class classification predictive tasks constructed from radiomics features extracted from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) pharmacokinetic (PK) protocol in discriminating among benign, borderline, and malignant ovarian tumors.
METHODS: One hundred and four ovarian lesions were evaluated using preoperative DCE-MRI. Radiomics features were extracted from 7 types of DCE-MR images. To explore the differential ability of radiomics between three types of ovarian tumors, two- and three-class classification tasks were established. The 2-class classification task was divided into three subtasks: benign vs. borderline (task A), benign vs. malignant (task B), and borderline vs. malignant (task C). For the 3-class classification task, 104 lesions were randomly divided into training (72 lesions) and validation (32 lesions) cohorts. The discrimination abilities of the radiomics signatures were established with the training cohort and tested with the independent validation cohort. The predictive performance of the task was evaluated by receiver operating characteristic (ROC) curve, calibration curve analysis, and decision curve analysis (DCA).
RESULTS: For the 2-class classification task, the combination of PK radiomics signatures model (PK model) showed a good diagnostic ability with the highest area under the ROC curves (AUCs) of 0.899, 0.865, and 0.893 for tasks A, B, and C, respectively. Additionally, the 3-class classification task demonstrated a good discrimination performance with AUCs of 0.893, 0.944, and 0.891 for the benign, borderline, and malignant groups, respectively.
CONCLUSIONS: Radiomics analysis based on the DCE-MRI PK protocol showed promise for discriminating among benign, borderline, and malignant ovarian tumors. KEY POINTS: • Two-class classification predictive task of DCE-MRI PK protocol enabled the classification of 3 categories of ovarian tumors through the pairwise comparison strategy with a perfect diagnostic ability. • Three-class classification predictive task maintained good performance to effectively judge each category of ovarian tumors directly.

Entities:  

Keywords:  Contrast media; Magnetic resonance imaging; Neoplasms; Ovary; Radiomics

Mesh:

Substances:

Year:  2020        PMID: 32767049     DOI: 10.1007/s00330-020-07112-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  3 in total

Review 1.  Ovarian surface epithelium: biology, endocrinology, and pathology.

Authors:  N Auersperg; A S Wong; K C Choi; S K Kang; P C Leung
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

2.  Texture features and pharmacokinetic parameters in differentiating benign and malignant breast lesions by dynamic contrast enhanced magnetic resonance imaging.

Authors:  Qingliang Niu; Xiaomei Jiang; Qin Li; Zhaolong Zheng; Hanwang Du; Shasha Wu; Xuexi Zhang
Journal:  Oncol Lett       Date:  2018-07-23       Impact factor: 2.967

3.  Measures of Diagnostic Accuracy: Basic Definitions.

Authors:  Ana-Maria Šimundić
Journal:  EJIFCC       Date:  2009-01-20
  3 in total
  9 in total

1.  Nomograms of Combining MRI Multisequences Radiomics and Clinical Factors for Differentiating High-Grade From Low-Grade Serous Ovarian Carcinoma.

Authors:  Cuiping Li; Hongfei Wang; Yulan Chen; Chao Zhu; Yankun Gao; Xia Wang; Jiangning Dong; Xingwang Wu
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

2.  Clinical Analysis of 137 Cases of Ovarian Tumors in Pregnancy.

Authors:  Qi Yin; Min Zhong; Zhihui Wang; XiuJie Sheng
Journal:  J Oncol       Date:  2022-05-25       Impact factor: 4.501

3.  Multi-Parametric Magnetic Resonance Imaging-Based Radiomics Analysis of Cervical Cancer for Preoperative Prediction of Lymphovascular Space Invasion.

Authors:  Gang Huang; Yaqiong Cui; Ping Wang; Jialiang Ren; Lili Wang; Yaqiong Ma; Yingmei Jia; Xiaomei Ma; Lianping Zhao
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

4.  Assessing Histology Structures by Ex Vivo MR Microscopy and Exploring the Link Between MRM-Derived Radiomic Features and Histopathology in Ovarian Cancer.

Authors:  Marion Tardieu; Yulia Lakhman; Lakhdar Khellaf; Maida Cardoso; Olivia Sgarbura; Pierre-Emmanuel Colombo; Mireia Crispin-Ortuzar; Evis Sala; Christophe Goze-Bac; Stephanie Nougaret
Journal:  Front Oncol       Date:  2022-01-19       Impact factor: 6.244

Review 5.  Progress of MRI Radiomics in Hepatocellular Carcinoma.

Authors:  Xue-Qin Gong; Yun-Yun Tao; Yao-Kun Wu; Ning Liu; Xi Yu; Ran Wang; Jing Zheng; Nian Liu; Xiao-Hua Huang; Jing-Dong Li; Gang Yang; Xiao-Qin Wei; Lin Yang; Xiao-Ming Zhang
Journal:  Front Oncol       Date:  2021-09-20       Impact factor: 6.244

6.  T2-weighted MRI-based radiomics for discriminating between benign and borderline epithelial ovarian tumors: a multicenter study.

Authors:  Mingxiang Wei; Yu Zhang; Genji Bai; Cong Ding; Haimin Xu; Yao Dai; Shuangqing Chen; Hong Wang
Journal:  Insights Imaging       Date:  2022-08-09

7.  Preoperative Prediction of Metastasis for Ovarian Cancer Based on Computed Tomography Radiomics Features and Clinical Factors.

Authors:  Yao Ai; Jindi Zhang; Juebin Jin; Ji Zhang; Haiyan Zhu; Xiance Jin
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

Review 8.  Serous borderline ovarian tumours: an extensive review on MR imaging features.

Authors:  Hilal Sahin; Asli Irmak Akdogan; Janette Smith; Jeries Paolo Zawaideh; Helen Addley
Journal:  Br J Radiol       Date:  2021-07-08       Impact factor: 3.629

Review 9.  Radiomics in Oncology, Part 2: Thoracic, Genito-Urinary, Breast, Neurological, Hematologic and Musculoskeletal Applications.

Authors:  Damiano Caruso; Michela Polici; Marta Zerunian; Francesco Pucciarelli; Gisella Guido; Tiziano Polidori; Federica Landolfi; Matteo Nicolai; Elena Lucertini; Mariarita Tarallo; Benedetta Bracci; Ilaria Nacci; Carlotta Rucci; Marwen Eid; Elsa Iannicelli; Andrea Laghi
Journal:  Cancers (Basel)       Date:  2021-05-29       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.